New blood test could help guide prostate cancer treatment
NCT ID NCT06762379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new algorithm that uses a liquid biopsy (a simple blood test) to find HRR gene mutations in patients with metastatic prostate cancer. It is for patients whose tumor tissue is not available or is inadequate for standard testing. The goal is to see if this method works well, which could help doctors choose the right treatments for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a reliable way to test for HRR gene mutations using a simple blood test, helping guide treatment decisions for patients who cannot provide tumor tissue.
- What could go wrong
- This is a small, early-stage study focused on testing a new method, not on treating the disease. The algorithm may not be accurate enough or may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
European Institute of oncology
RECRUITINGMilan, Italy, 20141, Italy